

Last updated on May 31, 2025	
Name of the issuer:	Rainbow Childrens Medicare Limited
1	Type of Issue
	Initial Public Offer
2	Issue Size (Rs. Mn)
	15,808.49
	Fresh Issue Size (Rs. Millions)
	2,800.00
	Offer for Sale Component (Rs. Millions)
	13,008.49

Source: Prospectus

3	Grade of issue along with name of the rating agency	
	Name	NA
	Grade	NA
4	Subscription Level (Number of times)	8.82999*

*Source: Final post issue report dated May 12, 2022

5	QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges	
	Particulars	%
	(i) On Allotment *	7.46%
	(ii) at the end of the 1st Quarter immediately after the listing of the issue (December 31, 2022)	17.68%
	(iii) at the end of 1st FY (March 31, 2023)	35.20%
	(iv) at the end of 2nd FY (March 31, 2024)**	38.80%
	(v) at the end of 3rd FY (March 31, 2025)**	38.39%

*Shareholding Pattern disclosed to Stock Exchanges

**QIB Holding not disclosed as reporting for relevant period has not been completed

6	Financials of the issuer			(In Rs Million)
	Parameters	1st FY (March 31, 2023)	2nd FY (March 31, 2024)	3rd FY (March 31, 2025)
	Income from operations	11,735.74	12,969.00	15,158.66
	Net Profit for the period	694.02	2,182.87	2,442.27
	Paid-up equity share capital	1,015.02	1,015.02	1,015.52
	Reserves	9,868.86	11,574.25	13,666.41

7	Trading status in the scrip of the issuer	
	Company's Equity Shares are listed on both BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE")	
	Particulars	Status
	(i) at the end of 1st FY (March 31, 2023)	Frequently Traded
	(ii) at the end of 2nd FY (March 31, 2024)	Frequently Traded
	(iii) at the end of 3rd FY (March 31, 2025)*	Frequently Traded

(*) will be updated in due course

8	Change, if any, in directors of issuer from the disclosures in the offer document		
	Particulars	Name of Director	Appointed / Resigned
	During year ended March 31, 2023	Nil	Nil
	During year ended March 31, 2024	Mr Anil Dhawan	Appointed
	During year ended March 31, 2025 ⁽¹⁾	Nil	Nil

1) Information shall be updated in due course

9	Status of implementation of project/ commencement of commercial production	
	Particulars	Remarks
	(i) as disclosed in the offer document	
	(ii) Actual implementation	Not Applicable
	(iii) Reasons for delay in implementation, if any	

10	Status of utilization of issue proceeds				
	(i) As disclosed in the offer document	Amount proposed to be utilised from Net Proceeds	Amount to be deployed from the Net Proceeds in Fiscal 2023	Amount to be deployed from the Net Proceeds in Fiscal 2024	Amount to be deployed from the Net Proceeds in Fiscal 2025
	Particulars	(in Rs Mn)			
	Early redemption of NCDs issued by our Company to CDC Emerging Markets Limited ("CDEML"), one of our Group Companies, in full	400	400		
	Capital expenditure towards setting up of new hospitals and purchase of medical equipment for such new hospitals	1700	1065	435	200
	General corporate purposes	562	562		
	Total	2662	2027	435	200
	(ii) Actual utilization	Amount proposed to be utilised from Net Proceeds (As per document)	Amount proposed to be utilised from Net Proceeds (Revised cost)	Total Amount utilized	Amount unutilized
	Particulars	(in Rs Mn)	(in Rs Mn)	(in Rs Mn)	(in Rs Mn)
	Early redemption of NCDs issued by our Company to CDC Emerging Markets Limited ("CDEML"), one of our Group Companies, in full	400	400	400	0
	Capital expenditure towards setting up of new hospitals and purchase of medical equipment for such new hospitals	1700	1700	1700	0
	General corporate purposes*	576	576	576	0
	Total	2676	2676	2676	0
	* During the quarter ended September 2023, the company has received an amount of 14.70 million towards the Company's share of unspent IP? expenses. The Board of directors of the company has approved to spend the amount of Rs. 14.70 million towards the General corporate purposes in the meeting held on 30th Oct 2023. After this change, amount to be utilized for General Corporate purpose is Rs. 576.10 million				
	(iii) Reasons for deviation, if any	Not Applicable			

Source: Monitoring agency report for the quarter ended June 30, 2024

11	Comments of monitoring agency, if applicable	Not Available
12	Price-related data	
	Designated SE	NSE
	Issue Price (Rs.)	542
	Listing Date	5/10/2022

Price parameters	At close of listing day May 10, 2022	At close of 30th calendar day from listing day	At close of 90th calendar day from listing day	As at the end of March 31, 2023		
				Closing price during FY	High during FY	Low during FY
Market Price	450.2	467	472.6	730.5	739	723.6
Nifty 50	16,240.05	16,356.25	17,397.50	17,359.75	18,812.50	15,293.50
Sectoral Index			Not Applicable			
Price parameters	As at the end of March 31, 2024			As at the end of March 31, 2025		
	Closing price during FY	High during FY	Low during FY	Closing price during FY	High during FY	Low during FY
Market Price	1297.55	1429.2	410	1,401.70	1,677.25	1,105.10
Nifty 50	22326.9	22493.55	17398.05	23,519.35	26,216.05	21,884.50
Sectoral Index			Not Applicable			

Source: Stock Exchange data. Where the 30th day / 90th day/ March 31 of a particular year falls on a holiday, the immediately following trading day has been considered

13	Basis for Issue Price				
	Accounting ratio	As disclosed in offer document*	At the end of 1st FY (March 31, 2023)	At the end of 2nd FY (March 31, 2024)	At the end of 3rd FY (March 31, 2025)**
EPS (Basic)	Issuer:				
	Consolidated (Basic)	4.36	20.89	21.38	21.38
	Industry Average - Peer Group (consolidated basis unless otherwise available only on standalone basis)				
	Apollo Hospitals Enterprise Limited	10.74	56.97	62.5	100.26
	Fortis Healthcare Limited	-1.45	7.8	7.93	10.26
	Narayana Hrudalaya Limited	-0.7	13.08	38.86	38.9
	Max Healthcare Institute Limited	-1.59	7.16	10.89	11.07
	Krishna Institute of Medical Sciences	26.42	42.03	38.57	9.61
	Peer Group: (Average)	6.684	25.408	31.75	34.02
P/E	Issuer:				
	Consolidated (Basic)	124.31	34.97	60.69	65.56
	Industry Average - Peer Group (consolidated basis unless otherwise available only on standalone basis)				
	Apollo Hospitals Enterprise Limited	438.88	75.64	101.63	66.05
	Fortis Healthcare Limited	N.A. since EPS is negative	33.33	52.95	68.08
	Narayana Hrudalaya Limited	N.A. since EPS is negative	59.18	32.95	43.48
	Max Healthcare Institute Limited	N.A. since EPS is negative	61.59	75.34	99.07
	Krishna Institute of Medical Sciences	54.19	33.46	53.36	66.52
	Peer Group: (Average)	241.535	52.64	63.24	68.64
RoNW %	Issuer:				
	Consolidated (Basic)	8.88	6.38	17.34	16.63%
	Industry Average - Peer Group (consolidated basis unless otherwise available only on standalone basis)				
	Apollo Hospitals Enterprise Limited	3.3	13.65	12.96	18.33%
	Fortis Healthcare Limited	-0.75	8.74	7.82	9.08%
	Narayana Hrudalaya Limited	-1.46	18.09	27.37	21.78%
	Max Healthcare Institute Limited	-2.47	9.86	1.26	11.47%
	Krishna Institute of Medical Sciences Limited	23.74	15.12	16.98	19.40%
	Peer Group: (Average)	4.472	13.092	13.28	16.01%
NAV per share	Issuer:				
	Consolidated (Basic)	86.07	213.73	124.62	145.32
	Industry Average - Peer Group (consolidated basis unless otherwise available only on standalone basis)				
	Apollo Hospitals Enterprise Limited	320.1	43.05	509.13	601.73
	Fortis Healthcare Limited	81.06	9.59	114.66	121.46
	Narayana Hrudalaya Limited	54.82	7.19	141.18	177.54
	Max Healthcare Institute Limited	58.37	7.25	865.11	96.50
	Krishna Institute of Medical Sciences	111.32	208.62	261.56	60.47
	Peer Group: (Average)	125.134	55.14	378.33	211.54

Notes

**Not available as the relevant fiscal years have not been completed/ information not disclosed

Key ratios for the Company for the three fiscal years stated above are/shall be calculated as follows:

(i) Basic earnings per Equity Share are computed in accordance with Indian Accounting Standard 33 'Earnings per Share' for issuer company, notified by the Companies (Indian Accounting Standards) Rules, 2015, as amended.

(ii) P/E - Closing Market Price as of relevant fiscal year end on BSE / Basic EPS for year/period for the relevant year

(iii) RoNW - Return on net worth (%) is net profit after tax divided by net worth at the end of the year/period. Net Worth = Equity Share Capital + Reserves & surplus excluding revaluation reserves

(iv) NAV per share - Networth at the end of the year / Shares Outstanding as of fiscal year end

14	Any other material information	Announcement
	Date	
	5/27/2022	Company has informed the Exchange that the Board of Directors in their meeting held on May 27, 2022 approved following matters:1. The
	6/9/2022	Submission of Disclosures of Related Party Transactions for the half year ended 31st March, 2022 pursuant to Regulation 23(9) of the SEBI
	6/10/2022	Company has informed the Exchanges that pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations,
	8/8/2022	Rainbow Children's Medicare Limited has informed the Exchange about :1. The unaudited Standalone and Consolidated Financial Results
	8/8/2022	Rainbow Children's Medicare Limited has informed the Exchange that Record date for the purpose of Final Dividend for Financial Year 2021-22
	8/29/2022	Rainbow Children's Medicare Limited (Rainbow/Company) on August 29, 2022 has inaugurated a new 55-beds spoke hospital, located at OMR
	3/1/2023	Commencement of a new 100 bed spoke hospital at Financial District, Hyderabad,Telangana.
	4/15/2023	Appointment of Mr Sanjeev Sukumaran as Group Chief Operating Officer (CMO) of the company w.e.f. April 15, 2023.
	5/14/2023	Appointment of Mr Anil Dhawan as Non- Executive Independent Director of the company w.e.f. August 30, 2023
	5/14/2023	Appointment of M/s. S. R. Batliboi & Associates LLP, Chartered Accountants (ICAI Firm Registration No. 101049W/ E300004) as the Statutory
	5/31/2023	Resignation of Mr R Gowrisankar as Chief Financial Officer of the company w.e.f. May 31, 2023
	7/17/2024	Allotment of Equity Shares under "Rainbow Children's Medicare Limited - Employee Stock Unit Plan 2023"
	8/13/2024	Appointment of Mr. K V S Subramanyam, Company Secretary in practice as secretarial auditor of the Company for the Financial year 2024-25
	8/13/2024	Monitoring agency report for the quarter ended June 30, 2024.
	8/22/2024	Allotment of Equity Shares under "Rainbow Children's Medicare Limited- Employee Stock Unit Plan 2023"
	12/13/2024	Intimation regarding resignation of Company Secretary and Compliance Officer
	12/26/2024	closure of trading window
	2/2/2025	Approval of "Rainbow Children's Medicare Limited - Employee Stock Option Scheme 2025
	2/9/2025	Statement on Deviation or Variation in utilisation of funds raised through Initial Public Offer (IPO)
	2/9/2025	Monitoring Agency Report for the quarter ended December 31, 2024
	5/13/2025	Monitoring Agency Report for the quarter ended March 31, 2025
	5/24/2025	The record date for payment of final dividend has been fixed as June 28, 2025

Disclaimer:

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by IIFL Securities Limited arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012. This information is gathered from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and / or the National Stock Exchange of India Limited ("NSE") and together with the BSE, the "Stock Exchanges") from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

Notwithstanding the above, IIFL Securities Limited does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein and shall not be liable in any manner for the same. Neither IIFL Securities Limited nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits incidental or consequential damage, howsoever arising, suffered or incurred by any person accessing and / or using this information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement.